Literature DB >> 11891271

Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice.

Mohammed Kashani-Sabet1, Yong Liu, Sylvia Fong, Pierre-Yves Desprez, Shuqing Liu, Guanghuan Tu, Mehdi Nosrati, Chakkrapong Handumrongkul, Denny Liggitt, Ann D Thor, Robert J Debs.   

Abstract

To date, functional genomic studies have been confined to either cell-based assays or germline mutations, using transgenic or knockout animals. However, these approaches are often unable either to recapitulate complex biologic phenotypes, such as tumor metastasis, or to identify the specific genes and functional pathways that produce serious diseases in adult animals. Although the transcription factor NF-kappaB transactivates many metastasis-related genes in cells, the precise genes and functional-pathways through which NF-kappaB regulates metastasis in tumor-bearing hosts are poorly understood. Here, we show that the systemic delivery of plasmid-based ribozymes targeting NF-kappaB in adult, tumor-bearing mice suppressed NF-kappaB expression in metastatic melanoma cells, as well as in normal cell types, and significantly reduced metastatic spread. Plasmid-based ribozymes suppressed target-gene expression with sequence specificity not achievable by using synthetic oligonucleotide-based approaches. NF-kappaB seemed to regulate tumor metastasis through invasion-related, rather than angiogenesis-, cell-cycle- or apoptosis-related pathways in tumor-bearing mice. Furthermore, ribozymes targeting either of the NF-kappaB-regulated genes, integrin beta(3) or PECAM-1 (a ligand-receptor pair linked to cell adhesion), reduced tumor metastasis at a level comparable to NF-kappaB. These studies demonstrate the utility of gene targeting by means of systemic, plasmid-based ribozymes to dissect out the functional genomics of complex biologic phenotypes, including tumor metastasis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11891271      PMCID: PMC122617          DOI: 10.1073/pnas.002025599

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Cancer. Improved mouse models.

Authors:  A Berns
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

2.  NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.

Authors:  D C Guttridge; C Albanese; J Y Reuther; R G Pestell; A S Baldwin
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

Review 3.  Activators and target genes of Rel/NF-kappaB transcription factors.

Authors:  H L Pahl
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

4.  Systemic gene delivery expands the repertoire of effective antiangiogenic agents.

Authors:  Y Liu; A Thor; E Shtivelman; Y Cao; G Tu; T D Heath; R J Debs
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

5.  Non-replicating Epstein-Barr virus-based plasmids extend gene expression and can improve gene therapy in vivo.

Authors:  G Tu; A L Kirchmaier; D Liggitt; Y Liu; S Liu; W H Yu; T D Heath; A Thor; R J Debs
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

6.  Role of NF-kappaB in p53-mediated programmed cell death.

Authors:  K M Ryan; M K Ernst; N R Rice; K H Vousden
Journal:  Nature       Date:  2000-04-20       Impact factor: 49.962

7.  Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.

Authors:  P A Pavco; K S Bouhana; A M Gallegos; A Agrawal; K S Blanchard; S L Grimm; K L Jensen; L E Andrews; F E Wincott; P A Pitot; R J Tressler; C Cushman; M A Reynolds; T J Parry
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

Review 8.  Molecular role(s) for integrins in human melanoma invasion.

Authors:  R E Seftor; E A Seftor; M J Hendrix
Journal:  Cancer Metastasis Rev       Date:  1999       Impact factor: 9.264

9.  Integrin involvement in glioblastoma multiforme: possible regulation by NF-kappaB.

Authors:  C K Ritchie; A Giordano; K Khalili
Journal:  J Cell Physiol       Date:  2000-08       Impact factor: 6.384

10.  Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8.

Authors:  S Huang; J B Robinson; A Deguzman; C D Bucana; I J Fidler
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

View more
  11 in total

1.  Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression.

Authors:  Horace DeLisser; Yong Liu; Pierre-Yves Desprez; Ann Thor; Paraskevei Briasouli; Chakrapong Handumrongkul; Jonathon Wilfong; Garret Yount; Mehdi Nosrati; Sylvia Fong; Emma Shtivelman; Melane Fehrenbach; Gaoyuan Cao; Dan H Moore; Shruti Nayak; Shruti Nyack; Denny Liggitt; Mohammed Kashani-Sabet; Robert Debs
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-06       Impact factor: 11.205

2.  Genes and pathways downstream of telomerase in melanoma metastasis.

Authors:  Sepideh Bagheri; Mehdi Nosrati; Shang Li; Sylvia Fong; Sima Torabian; Javier Rangel; Dan H Moore; Scot Federman; Rebecca R Laposa; Frederick L Baehner; Richard W Sagebiel; James E Cleaver; Christopher Haqq; Robert J Debs; Elizabeth H Blackburn; Mohammed Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-17       Impact factor: 11.205

3.  Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth.

Authors:  Jinming Yang; Wei-Hua Pan; Gary A Clawson; Ann Richmond
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

4.  Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis.

Authors:  David De Semir; Mehdi Nosrati; Vladimir Bezrookove; Altaf A Dar; Scot Federman; Geraldine Bienvenu; Suraj Venna; Javier Rangel; Joan Climent; Tanja M Meyer Tamgüney; Suresh Thummala; Schuyler Tong; Stanley P L Leong; Chris Haqq; Paul Billings; James R Miller; Richard W Sagebiel; Robert Debs; Mohammed Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-17       Impact factor: 11.205

5.  Ribozyme-mediated targeting of IkappaBgamma inhibits melanoma invasion and metastasis.

Authors:  Sima Z Torabian; David de Semir; Mehdi Nosrati; Sepideh Bagheri; Altaf A Dar; Sylvia Fong; Yong Liu; Scot Federman; Jeff Simko; Chris Haqq; Robert J Debs; Mohammed Kashani-Sabet
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

Review 6.  EZH2 as a mediator of treatment resistance in melanoma.

Authors:  Jessamy C Tiffen; Stuart J Gallagher; Hsin-Yi Tseng; Fabian V Filipp; Barbara Fazekas de St. Groth; Peter Hersey
Journal:  Pigment Cell Melanoma Res       Date:  2016-05-25       Impact factor: 4.693

7.  Functional identification of distinct sets of antitumor activities mediated by the FKBP gene family.

Authors:  Sylvia Fong; Leslie Mounkes; Yong Liu; Michael Maibaum; Eric Alonzo; Pierre-Yves Desprez; Ann D Thor; Mohammed Kashani-Sabet; Robert J Debs
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-11       Impact factor: 11.205

Review 8.  NF-κB as potential target in the treatment of melanoma.

Authors:  Gabriele Madonna; Claudio Dansky Ullman; Giusy Gentilcore; Giuseppe Palmieri; Paolo Antonio Ascierto
Journal:  J Transl Med       Date:  2012-03-20       Impact factor: 5.531

9.  MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma.

Authors:  Liron Zehavi; Hagit Schayek; Jasmine Jacob-Hirsch; Yechezkel Sidi; Raya Leibowitz-Amit; Dror Avni
Journal:  Mol Cancer       Date:  2015-03-26       Impact factor: 27.401

10.  A structural analysis of in vitro catalytic activities of hammerhead ribozymes.

Authors:  Yu Shao; Susan Wu; Chi Yu Chan; Jessie R Klapper; Erasmus Schneider; Ye Ding
Journal:  BMC Bioinformatics       Date:  2007-11-30       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.